FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2017383791> ?p ?o ?g. }

• W2017383791 endingPage "496" @default.
• W2017383791 startingPage "489" @default.
• W2017383791 abstract "The effectiveness of Helicobacter pylori eradication regimens has not been extensively investigated in the clinical practice setting. The optimal treatment choice after an initial failed eradication attempt has not been determined.To evaluate proton pump inhibitor-based triple therapies as first-line eradication regimens in clinical practice, and to establish the efficacy of second-line regimens in the context of an initial failed eradication attempt.Three hundred and eight patients with dyspepsia and evidence of H. pylori at endoscopy were recruited. As first-line therapy, 116 patients received omeprazole 20 mg b.d. in combination with amoxycillin 1 g b.d. and clarithromycin 500 mg b.d. (OAC) while 192 patients received omeprazole 20 mg b.d. in combination with metronidazole 400 mg b.d. and clarithromycin 250 mg b.d. (OMC). H. pylori status was reassessed at least 4 weeks after therapy (25 patients failed to attend for further testing). Of 52 patients with an initial failed eradication attempt, 20 patients received a 1 week quadruple therapy regimen incorporating omeprazole 20 mg b.d., tripotassium dicitrato bismuthate 120 mg q.d.s., tetracycline 500 mg q.d.s. and metronidazole 400 mg t.d.s., 20 patients received a 2-week proton pump inhibitor-based triple therapy regimen as described, and 12 patients received a further 1-week proton pump inhibitor-based triple therapy regimen.Including 308 patients, the intention-to-treat (ITT) eradication rates for OAC and OMC as first-line regimens were 72% (95% CI: 63-80%) and 73% (95% CI: 67-79%) respectively. A per protocol (PP) analysis on the 283 patients who completed follow-up gives an initial eradication rate of 78% (95% CI: 69-86%) for OAC and 79% (95% CI: 73-85%) for OMC. There were 60 patients (21%; 95% CI: 17-26%) in whom the initial eradication attempt was unsuccessful. With second-line therapy, H. pylori was successfully eradicated in a further 35/52 (67%; 95% CI: 58-73%) patients. The eradication rates with the quadruple regimen and 2-week triple therapy regimens were 75% (95% CI: 56-94%) and 80% (95% CI: 63-98%) respectively (P = 0. 71). The eradication rate with a repeat 1-week regimen was 33% (95% CI: 7-60%).The eradication rates achieved in this 'in practice' study with recommended first-line 1-week proton pump inhibitor-based triple therapy regimens were lower than the rates achieved with similar regimens in the clinical trial setting. A repeat 1-week proton pump inhibitor-based triple therapy regimen was not successful as a salvage therapy. Both the 2-week proton pump inhibitor-based triple therapy regimen and the 1-week quadruple therapy regimen were successful second-line treatments in >/=75% of patients." @default.
• W2017383791 created "2016-06-24" @default.
• W2017383791 creator A5007461551 @default.
• W2017383791 creator A5034097034 @default.
• W2017383791 creator A5049937107 @default.
• W2017383791 creator A5086893512 @default.
• W2017383791 creator A5088256534 @default.
• W2017383791 date "1999-04-01" @default.
• W2017383791 modified "2023-10-17" @default.
• W2017383791 title "Treatment options for <i>Helicobacter pylori</i> infection when proton pump inhibitor‐based triple therapy fails in clinical practice" @default.
• W2017383791 cites W1964065632 @default.
• W2017383791 cites W1970636233 @default.
• W2017383791 cites W1989726504 @default.
• W2017383791 cites W1990997207 @default.
• W2017383791 cites W1992436643 @default.
• W2017383791 cites W1996405559 @default.
• W2017383791 cites W2002005019 @default.
• W2017383791 cites W2018742172 @default.
• W2017383791 cites W2020477949 @default.
• W2017383791 cites W2029865847 @default.
• W2017383791 cites W2033468305 @default.
• W2017383791 cites W2034022551 @default.
• W2017383791 cites W2034641738 @default.
• W2017383791 cites W2045431197 @default.
• W2017383791 cites W2047048118 @default.
• W2017383791 cites W2048076239 @default.
• W2017383791 cites W2057863812 @default.
• W2017383791 cites W2060392717 @default.
• W2017383791 cites W2060942268 @default.
• W2017383791 cites W2072396675 @default.
• W2017383791 cites W2078125568 @default.
• W2017383791 cites W2089759115 @default.
• W2017383791 cites W2089783726 @default.
• W2017383791 cites W2091711815 @default.
• W2017383791 cites W2094331860 @default.
• W2017383791 cites W2123848597 @default.
• W2017383791 cites W2138042459 @default.
• W2017383791 cites W2138438059 @default.
• W2017383791 cites W214501741 @default.
• W2017383791 cites W2148899552 @default.
• W2017383791 cites W2162890832 @default.
• W2017383791 cites W2166151867 @default.
• W2017383791 cites W2326140796 @default.
• W2017383791 cites W4237403611 @default.
• W2017383791 doi "https://doi.org/10.1046/j.1365-2036.1999.00504.x" @default.
• W2017383791 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10215733" @default.
• W2017383791 hasPublicationYear "1999" @default.
• W2017383791 type Work @default.
• W2017383791 sameAs 2017383791 @default.
• W2017383791 citedByCount "123" @default.
• W2017383791 countsByYear W20173837912012 @default.
• W2017383791 countsByYear W20173837912013 @default.
• W2017383791 countsByYear W20173837912014 @default.
• W2017383791 countsByYear W20173837912016 @default.
• W2017383791 countsByYear W20173837912017 @default.
• W2017383791 countsByYear W20173837912018 @default.
• W2017383791 countsByYear W20173837912020 @default.
• W2017383791 countsByYear W20173837912023 @default.
• W2017383791 crossrefType "journal-article" @default.
• W2017383791 hasAuthorship W2017383791A5007461551 @default.
• W2017383791 hasAuthorship W2017383791A5034097034 @default.
• W2017383791 hasAuthorship W2017383791A5049937107 @default.
• W2017383791 hasAuthorship W2017383791A5086893512 @default.
• W2017383791 hasAuthorship W2017383791A5088256534 @default.
• W2017383791 hasConcept C126322002 @default.
• W2017383791 hasConcept C141071460 @default.
• W2017383791 hasConcept C151730666 @default.
• W2017383791 hasConcept C2776409635 @default.
• W2017383791 hasConcept C2776962512 @default.
• W2017383791 hasConcept C2777396551 @default.
• W2017383791 hasConcept C2777498785 @default.
• W2017383791 hasConcept C2779343474 @default.
• W2017383791 hasConcept C2779708577 @default.
• W2017383791 hasConcept C2781025758 @default.
• W2017383791 hasConcept C2781413609 @default.
• W2017383791 hasConcept C501593827 @default.
• W2017383791 hasConcept C71924100 @default.
• W2017383791 hasConcept C86803240 @default.
• W2017383791 hasConcept C89423630 @default.
• W2017383791 hasConcept C90924648 @default.
• W2017383791 hasConceptScore W2017383791C126322002 @default.
• W2017383791 hasConceptScore W2017383791C141071460 @default.
• W2017383791 hasConceptScore W2017383791C151730666 @default.
• W2017383791 hasConceptScore W2017383791C2776409635 @default.
• W2017383791 hasConceptScore W2017383791C2776962512 @default.
• W2017383791 hasConceptScore W2017383791C2777396551 @default.
• W2017383791 hasConceptScore W2017383791C2777498785 @default.
• W2017383791 hasConceptScore W2017383791C2779343474 @default.
• W2017383791 hasConceptScore W2017383791C2779708577 @default.
• W2017383791 hasConceptScore W2017383791C2781025758 @default.
• W2017383791 hasConceptScore W2017383791C2781413609 @default.
• W2017383791 hasConceptScore W2017383791C501593827 @default.
• W2017383791 hasConceptScore W2017383791C71924100 @default.
• W2017383791 hasConceptScore W2017383791C86803240 @default.
• W2017383791 hasConceptScore W2017383791C89423630 @default.
• W2017383791 hasConceptScore W2017383791C90924648 @default.
• W2017383791 hasIssue "4" @default.
• W2017383791 hasLocation W20173837911 @default.

• next